bioXXmed AG Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-996.91	-20,949	-0.83	-	-1.84	Upgrade
Depreciation & Amortization	0.09	-	0.01	-	0.02	Upgrade
Other Operating Activities	995.91	20,948	0.01	-	0	Upgrade
Change in Inventory	-	-	-0	-	-	Upgrade
Change in Accounts Payable	-	-	-0.09	-	-	Upgrade
Change in Other Net Operating Assets	-	-	-	-	0.16	Upgrade
Operating Cash Flow	-0.92	-0.73	-0.91	-	-1.66	Upgrade
Capital Expenditures	-	-	-0	-	-0	Upgrade
Investment in Securities	-	-	-1.5	-	-4.8	Upgrade
Other Investing Activities	-0.29	-0.5	0.03	-	-	Upgrade
Investing Cash Flow	-0.29	-0.5	-1.47	-	-4.8	Upgrade
Long-Term Debt Repaid	-	-	-0.12	-	-	Upgrade
Total Debt Repaid	-	-	-0.12	-	-	Upgrade
Net Debt Issued (Repaid)	-	-	-0.12	-	-	Upgrade
Issuance of Common Stock	-	-	4.38	-	6.02	Upgrade
Other Financing Activities	0.85	-	-0.04	-	-	Upgrade
Financing Cash Flow	0.85	-	4.22	-	6.02	Upgrade
Net Cash Flow	-0.36	-1.23	1.84	-	-0.44	Upgrade
Free Cash Flow	-0.92	-0.73	-0.91	-	-1.66	Upgrade
Free Cash Flow Margin	-26223.88%	-4194.44%	-7473.42%	-	-4613.89%	Upgrade
Free Cash Flow Per Share	-0.67	-1.42	-1.78	-	-4.12	Upgrade
Cash Interest Paid	-	-	0.04	-	-	Upgrade
Levered Free Cash Flow	-0.47	-0.52	-0.67	-	-0.96	Upgrade
Unlevered Free Cash Flow	-0.47	-0.52	-0.64	-	-0.96	Upgrade
Change in Working Capital	-	-	-0.09	-	0.16	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.